• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

    3/12/24 5:36:05 AM ET
    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Parts:O.E.M.
    Consumer Discretionary
    Get the next $ACAD alert in real time by email

    U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday.

    Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) fell sharply in today’s pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.

    ACADIA Pharmaceuticals shares dipped 17.4% to $19.93 in pre-market trading.

    Here are some big stocks recording losses in today’s pre-market trading session.

    • Power & Digital Infrastructure Acquisition II Corp. (NASDAQ:XPDB) shares tumbled 12.6% to $25.57 in pre-market trading after surging 181% on Monday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 5.9% to $9.16 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
    • Aeva Technologies, Inc. (NASDAQ:AEVA) shares declined 5.4% to $1.23 in pre-market trading. Aeva said it expects a 1-for-5 reverse stock split of its outstanding shares of common stock will be effective as of March 18, 2024.
    • PLDT Inc. (NYSE:PHI) fell 3.8% to $25.95 in pre-market trading after jumping over 16% on Monday.
    • NextNav Inc. (NASDAQ:NN) declined 3.6% to $5.07 in pre-market trading. NextNav shares jumped 35% on Monday after the company announced it signed an agreement to acquire spectrum licenses covering an additional 4 MHz in the lower 900 MHz band.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares fell 3.2% to $2.72 in pre-market trading. Lexicon shares surged over 29% on Monday after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.
    • Asana, Inc. (NYSE:ASAN) shares fell 2.4% to $18.35 in pre-market trading following fourth-quarter results.

     

    Now Read This: Top 5 Risk Off Stocks That May Plunge This Quarter

    Don’t forget to check out our premarket coverage here

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $AEVA
    $ASAN
    $LXRX

    CompanyDatePrice TargetRatingAnalyst
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    ACADIA Pharmaceuticals Inc.
    $ACAD
    3/25/2026$29.00Neutral → Buy
    BofA Securities
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    Asana Inc.
    $ASAN
    1/15/2026$16.00Neutral → Buy
    Citigroup
    Asana Inc.
    $ASAN
    12/17/2025Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    12/15/2025$18.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Asana from Underperform to Sector Perform and set a new price target of $7.00

    4/1/26 8:10:23 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    ACADIA Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00

    3/25/26 8:22:46 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

    Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb

    4/15/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aeva Announces Date for First Quarter 2026 Results and Conference Call

    Aeva® (NASDAQ:AEVA), a leader in next-generation sensing and perception systems, today announced it will report results for the first quarter 2026 after market close on Wednesday, May 6, 2026. Aeva will host a conference call and webcast to discuss the first quarter 2026 results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Event: Aeva Technologies, Inc. First Quarter 2026 Results Call Date: Wednesday, May 6, 2026 Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Join by webcast: investors.aeva.com An archive of the webcast will be available shortly after the call on our investor relations website investors.aeva.com for 12 months following the call. Abo

    4/15/26 7:00:00 AM ET
    $AEVA
    Auto Parts:O.E.M.
    Consumer Discretionary

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to six newly hired non-executive employees and to Mr. Jerome M. Gangitano, the Company's new SVP, CMC Technical Operations. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted to the six newly hired non-executive employees effective as of A

    4/14/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dugel Pravin

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    4/13/26 5:15:06 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Panlilio Alfredo Santos

    4 - PLDT Inc. (0000078150) (Issuer)

    4/13/26 7:47:07 AM ET
    $PHI
    Telecommunications Equipment
    Telecommunications

    SEC Form 4 filed by Schneyer Mark C.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    4/7/26 7:57:16 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by NextNav Inc.

    DEFA14A - NEXTNAV INC. (0001865631) (Filer)

    4/8/26 4:33:45 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    SEC Form DEF 14A filed by NextNav Inc.

    DEF 14A - NEXTNAV INC. (0001865631) (Filer)

    4/8/26 4:32:07 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by PLDT Inc. Sponsored ADR

    6-K - PLDT Inc. (0000078150) (Filer)

    4/1/26 7:09:16 AM ET
    $PHI
    Telecommunications Equipment
    Telecommunications

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana to Appoint Aziz Megji to the Role of Chief Financial Officer

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), the system of action where humans and AI run work together, will promote Aziz Megji to the role of Chief Financial Officer (CFO), effective March 24, 2026. Megji will succeed Sonalee Parekh, who has served as Asana's CFO since 2024 and tendered her resignation effective March 23, 2026. Megji brings his experience from his Head of Financial Planning & Analysis role where he led the company's annual planning, budgeting, forecasting, and performance management processes, as well as overseeing the strategic finance, treasury, investor relations, corporate development, deal desk, and sales compensation functions. He partners closely with Asana's CEO and Boa

    3/2/26 4:06:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    NextNav Appoints Lisa Hook to Board of Directors

    NextNav Expands Board with Appointment of Seasoned Technology and National Security Leader NextNav Inc. (NASDAQ:NN), a leader in next-generation terrestrial Positioning, Navigation, and Timing (PNT) and 3D geolocation solutions, today announced the appointment of Lisa Hook to its Board of Directors, effective February 24, 2026. Ms. Hook will also serve as Lead Independent Director and has been appointed as a member of the Company's Technology and National Defense and Compensation and Human Capital Committees. "I am delighted to welcome Lisa to the NextNav Board of Directors," said Mariam Sorond, NextNav's Chief Executive Officer and Board Chair. "Her leadership in global information ser

    2/27/26 11:53:00 AM ET
    $NN
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Financials

    Live finance-specific insights

    View All

    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

    Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb

    4/15/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aeva Announces Date for First Quarter 2026 Results and Conference Call

    Aeva® (NASDAQ:AEVA), a leader in next-generation sensing and perception systems, today announced it will report results for the first quarter 2026 after market close on Wednesday, May 6, 2026. Aeva will host a conference call and webcast to discuss the first quarter 2026 results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Event: Aeva Technologies, Inc. First Quarter 2026 Results Call Date: Wednesday, May 6, 2026 Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Join by webcast: investors.aeva.com An archive of the webcast will be available shortly after the call on our investor relations website investors.aeva.com for 12 months following the call. Abo

    4/15/26 7:00:00 AM ET
    $AEVA
    Auto Parts:O.E.M.
    Consumer Discretionary

    NextNav Inc. Reports Fourth Quarter and Full Year 2025 Results and Operational Highlights

    NextNav confident FCC moving toward near-term NPRM NextNav Inc. (NASDAQ:NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported its financial results and operational updates for the quarter ended and full year December 31, 2025. "We are confident the Federal Communications Commission (FCC) is moving toward a Notice of Proposed Rulemaking (NPRM) in the near term, supported by a robust and well‑developed record with a path to a Report and Order," said Mariam Sorond, CEO of NextNav. "FCC Chairman Brendan Carr's recent submission of a PNT rulemaking to the Office of Management and Budget represents an important milestone achieved in rapid

    3/17/26 4:05:00 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEVA
    $ASAN
    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NextNav Inc.

    SC 13D/A - NEXTNAV INC. (0001865631) (Subject)

    12/6/24 6:03:25 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care